Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump

Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump


Pfizer CEO Albert Bourla talks during a press conference with the president of the European Commission after a visit to oversee the production of the Pfizer-BioNTech Covid-19 vaccine at the factory of U.S. pharmaceutical company Pfizer, in Puurs, Belgium, April 23, 2021.

John Thys | AFP | Getty Images

Pfizer slashed its full-year earnings and revenue guidance on Friday, as it said demand for its Covid products has waned.

The company now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion. Pfizer said it cut its revenue outlook “solely due to its Covid products.”

The biopharmaceutical company slashed its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share, from a previous $3.25 to $3.45 per share.

Pfizer said it expects revenue from the Covid treatment Paxlovid to come in $7 billion lower than previously anticipated, in part due to the return of doses labeled for emergency use by the U.S. government. It also said it anticipates sales of its vaccine, Comirnaty, will be $2 billion lower than previously expected because of lower-than-expected vaccination rates.

Pfizer’s latest Covid booster became available in the U.S. last month, but the rollout has been rocky due to supply and insurance coverage issues. Fewer patients have also sought treatments for Covid than they did earlier in the pandemic, as vaccination and prior immunity lead to milder cases for many people.

Pfizer shares fell more than 3% in extended trading Friday.

Subscribe to CNBC on YouTube.



Source

Merck plans  billion cost cuts by end of 2027, narrows full-year outlook
Health

Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches […]

Read More
UnitedHealth says 2025 earnings will be worse than expected as high medical costs dog insurers
Health

UnitedHealth says 2025 earnings will be worse than expected as high medical costs dog insurers

UnitedHealthcare signage is displayed on an office building in Phoenix, Arizona, on July 19, 2023. Patrick T. Fallon | Afp | Getty Images UnitedHealth Group on Tuesday issued a 2025 outlook that fell short of Wall Street’s expectations, as the company’s insurance unit continues to grapple with higher medical costs. The company anticipates it will […]

Read More
UnitedHealth aims to reassure investors as profits plunge, DOJ investigates its Medicare business
Health

UnitedHealth aims to reassure investors as profits plunge, DOJ investigates its Medicare business

Omar Marques | Lightrocket | Getty Images UnitedHealth Group Chairman and CEO Stephen Hemsley will face the first real test Tuesday of his ability to regain investor confidence as the largest private U.S. insurer reports earnings. The Dow component has seen its share price cut nearly in half since mid-May, with the stock on pace […]

Read More